JP2020523330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523330A5 JP2020523330A5 JP2019568050A JP2019568050A JP2020523330A5 JP 2020523330 A5 JP2020523330 A5 JP 2020523330A5 JP 2019568050 A JP2019568050 A JP 2019568050A JP 2019568050 A JP2019568050 A JP 2019568050A JP 2020523330 A5 JP2020523330 A5 JP 2020523330A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- alkoxy
- alkyl
- haloalkyl
- thiazolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 isooxazolyl Chemical group 0.000 claims 29
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000001188 haloalkyl group Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 6
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 6
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 5
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000534944 Thia Species 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000002071 phenylalkoxy group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517259P | 2017-06-09 | 2017-06-09 | |
| US62/517,259 | 2017-06-09 | ||
| PCT/US2018/036635 WO2018227067A1 (en) | 2017-06-09 | 2018-06-08 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523330A JP2020523330A (ja) | 2020-08-06 |
| JP2020523330A5 true JP2020523330A5 (https=) | 2021-07-26 |
| JP7094989B2 JP7094989B2 (ja) | 2022-07-04 |
Family
ID=62751601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568050A Active JP7094989B2 (ja) | 2017-06-09 | 2018-06-08 | シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11180490B2 (https=) |
| EP (1) | EP3634958B1 (https=) |
| JP (1) | JP7094989B2 (https=) |
| KR (1) | KR102615098B1 (https=) |
| CN (1) | CN110997661B (https=) |
| ES (1) | ES2883701T3 (https=) |
| WO (1) | WO2018227067A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227065A1 (en) * | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| KR102803660B1 (ko) | 2018-03-05 | 2025-05-02 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| SG11202108552QA (en) * | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN116034104B (zh) * | 2020-07-09 | 2026-01-09 | 百时美施贵宝公司 | 氧代吡咯烷fpr2激动剂 |
| CA3185263A1 (en) * | 2020-07-09 | 2022-01-13 | James A. Johnson | Pyrazolone formyl peptide 2 receptor agonists |
| KR20230051525A (ko) * | 2020-08-12 | 2023-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 옥소피롤리딘 우레아 fpr2 효능제 |
| WO2022155860A1 (en) * | 2021-01-21 | 2022-07-28 | Biofront Therapeutics (Beijing) Co., Ltd. | Modulators of fpr1 and methods of using the same |
| EP4281452A4 (en) * | 2021-01-21 | 2024-11-06 | Beijing Tiantan Hospital | MODULATORS OF FPR1 AND METHODS OF USE THEREOF |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8492556B2 (en) | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| WO2014111465A1 (en) * | 2013-01-17 | 2014-07-24 | Sanofi | Isomannide derivatives as inhibitors of soluble epoxide hydrolase |
| NZ720508A (en) | 2013-11-28 | 2019-03-29 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| JP6746614B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| WO2016189876A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| MX2018005756A (es) | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| JP6811241B2 (ja) | 2015-12-10 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
| WO2018227065A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| KR102615095B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| KR102803660B1 (ko) | 2018-03-05 | 2025-05-02 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
-
2018
- 2018-06-08 EP EP18734735.6A patent/EP3634958B1/en active Active
- 2018-06-08 JP JP2019568050A patent/JP7094989B2/ja active Active
- 2018-06-08 KR KR1020207000303A patent/KR102615098B1/ko active Active
- 2018-06-08 CN CN201880050609.6A patent/CN110997661B/zh active Active
- 2018-06-08 ES ES18734735T patent/ES2883701T3/es active Active
- 2018-06-08 WO PCT/US2018/036635 patent/WO2018227067A1/en not_active Ceased
- 2018-06-08 US US16/619,961 patent/US11180490B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523330A5 (https=) | ||
| TWI441819B (zh) | 用於炎症及免疫相關用途之化合物 | |
| JP2006508065A5 (https=) | ||
| JP5702392B2 (ja) | キサンチンオキシダーゼ阻害剤として効果的な新規化合物、その製造方法及びそれを含有する医薬組成物 | |
| JP3600832B2 (ja) | 新規１，２，４−トリアゾール系化合物 | |
| JP5576485B2 (ja) | 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール | |
| TW200829585A (en) | Cyclohexenyl-aryl compounds for inflammation and immune-related uses | |
| US7951957B2 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| JP2013544854A5 (https=) | ||
| JP2020515589A5 (https=) | ||
| MXPA06013912A (es) | Ligandos del receptor de crth2 para usos medicinales. | |
| EA030698B1 (ru) | Ингибиторы деметилаз гистонов | |
| NZ545447A (en) | Compounds for inflammation and immune-related uses | |
| JP2011510080A5 (https=) | ||
| JP2009524677A (ja) | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 | |
| WO2009038775A1 (en) | Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | |
| JP2007505105A5 (https=) | ||
| CN106604918B (zh) | 多环hERG激活剂 | |
| JP6484168B2 (ja) | 抗ウイルス活性を有するメタンチオン化合物 | |
| JP2020517678A5 (https=) | ||
| TW202517249A (zh) | 含有缺氧誘導因子－脯醯胺羥基化酶抑制劑的長效口服藥物及其用途 | |
| JP7815213B2 (ja) | ベンジルアミン誘導体、その調製方法およびその用途 | |
| JP2007530594A (ja) | 炎症及び免疫に関連する用途に用いられるアクリロニトリル誘導体 | |
| CN101137624B (zh) | 用于炎症与免疫相关用途的化合物 | |
| WO2002018344A1 (en) | Novel ester or amide derivatives |